BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33007922)

  • 1. Identification of Plasma Glycosphingolipids as Potential Biomarkers for Prostate Cancer (PCa) Status.
    Snider AJ; Seeds MC; Johnstone L; Snider JM; Hallmark B; Dutta R; Moraga Franco C; Parks JS; Bensen JT; Broeckling CD; Mohler JL; Smith GJ; Fontham ETH; Lin HK; Bresette W; Sergeant S; Chilton FH
    Biomolecules; 2020 Sep; 10(10):. PubMed ID: 33007922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score.
    Markin PA; Brito A; Moskaleva N; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; La Frano MR; Appolonova SA
    Metabolomics; 2020 Jun; 16(7):74. PubMed ID: 32556743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
    Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
    Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer diagnosis and characterization with mass spectrometry imaging.
    Kurreck A; Vandergrift LA; Fuss TL; Habbel P; Agar NYR; Cheng LL
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):297-305. PubMed ID: 29209003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carotenoid intake and adipose tissue carotenoid levels in relation to prostate cancer aggressiveness among African-American and European-American men in the North Carolina-Louisiana prostate cancer project (PCaP).
    Antwi SO; Steck SE; Su LJ; Hebert JR; Zhang H; Craft NE; Fontham ET; Smith GJ; Bensen JT; Mohler JL; Arab L
    Prostate; 2016 Sep; 76(12):1053-66. PubMed ID: 27271547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
    Yu C; Niu L; Li L; Li T; Duan L; He Z; Zhao Y; Zou L; Wu X; Luo C
    Prostate; 2021 Dec; 81(16):1320-1328. PubMed ID: 34590739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer.
    Kuvibidila S; Rayford W
    J Lab Clin Med; 2006 Apr; 147(4):174-81. PubMed ID: 16581345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
    Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
    Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
    Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the Relationship between Environmental Arsenic and Prostate Cancer Aggressiveness among African-American and European-American Men in North Carolina.
    Parada H; Wu T; Fry RC; Farnan L; Smith GJ; Mohler JL; Bensen JT
    Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33198142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer.
    Dai L; Li J; Xing M; Sanchez TW; Casiano CA; Zhang JY
    Prostate; 2016 Nov; 76(15):1375-86. PubMed ID: 27418398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7.
    Falegan OS; Jarvi K; Vogel HJ; Hyndman ME
    Prostate; 2021 Aug; 81(11):713-720. PubMed ID: 34097313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical presentation of prostate cancer in black South Africans.
    Tindall EA; Monare LR; Petersen DC; van Zyl S; Hardie RA; Segone AM; Venter PA; Bornman MS; Hayes VM
    Prostate; 2014 Jun; 74(8):880-91. PubMed ID: 24723425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP.
    Steck SE; Arab L; Zhang H; Bensen JT; Fontham ET; Johnson CS; Mohler JL; Smith GJ; Su JL; Trump DL; Woloszynska-Read A
    PLoS One; 2015; 10(4):e0125151. PubMed ID: 25919866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy.
    Jeong IG; Dajani D; Verghese M; Hwang J; Cho YM; Hong JH; Kim CS; Ahn H; Ro JY
    Urol Oncol; 2016 Jan; 34(1):3.e9-14. PubMed ID: 26345648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
    Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
    Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive Serum Metabolomic Profiling Reveals Elevated Kynurenine Pathway's Metabolites in Humans with Prostate Cancer.
    Khan A; Choi SA; Na J; Pamungkas AD; Jung KJ; Jee SH; Park YH
    J Proteome Res; 2019 Apr; 18(4):1532-1541. PubMed ID: 30628444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
    Kiebish MA; Tekumalla P; Ravipaty S; Dobi A; Srivastava S; Wu W; Patil S; Friss T; Klotz A; Srinivasan A; Cullen J; Rosner IL; Ali A; Laszlo S; Petrovic M; Fleshner N; Garren J; Miller G; Mahaveer Chand N; Rodrigues LO; Granger E; Kellogg MD; Luan S; Diamandis E; Akmaev VR; Sarangarajan R; Bountra C; Freedland SJ; McLeod DG; Narain NR
    Sci Rep; 2021 Jul; 11(1):15052. PubMed ID: 34302010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
    Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
    PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association among plasma 1,25(OH)
    Ramakrishnan S; Steck SE; Arab L; Zhang H; Bensen JT; Fontham ETH; Johnson CS; Mohler JL; Smith GJ; Su LJ; Woloszynska A
    Prostate; 2019 Jul; 79(10):1117-1124. PubMed ID: 31077420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.